Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance.
Hansen D, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, Rössner S, Saris W, Van Gaal L, James W, Goulder M; STORM Study Group. Hansen D, et al. Among authors: van gaal l. Int J Obes Relat Metab Disord. 2001 Apr;25(4):496-501. doi: 10.1038/sj.ijo.0801481. Int J Obes Relat Metab Disord. 2001. PMID: 11319653 Clinical Trial.
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S, Savolainen MJ, Van Gaal L; NN8022-1807 Investigators. Astrup A, et al. Among authors: van gaal l. Int J Obes (Lond). 2012 Jun;36(6):843-54. doi: 10.1038/ijo.2011.158. Epub 2011 Aug 16. Int J Obes (Lond). 2012. PMID: 21844879 Free PMC article. Clinical Trial.
Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
Lean ME, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rössner S, Van Gaal L, Astrup A; NN8022-1807 Investigators. Lean ME, et al. Among authors: van gaal l. Int J Obes (Lond). 2014 May;38(5):689-97. doi: 10.1038/ijo.2013.149. Epub 2013 Aug 14. Int J Obes (Lond). 2014. PMID: 23942319 Free PMC article. Clinical Trial.
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial.
Seimon RV, Espinoza D, Finer N, James WP, Legler UF, Coutinho W, Sharma AM, Van Gaal L, Maggioni AP, Sweeting A, Torp-Pedersen C, Gebski V, Caterson ID. Seimon RV, et al. Among authors: van gaal l. Int J Obes (Lond). 2015 May;39(5):849-57. doi: 10.1038/ijo.2014.211. Epub 2014 Dec 18. Int J Obes (Lond). 2015. PMID: 25520249 Clinical Trial.
Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP; SCOUT Investigators. Sharma AM, et al. Among authors: van gaal l. Diabetes Obes Metab. 2009 Mar;11(3):239-50. doi: 10.1111/j.1463-1326.2008.00930.x. Epub 2008 Jul 29. Diabetes Obes Metab. 2009. PMID: 18671798 Clinical Trial.
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL; SCOUT Investigators. James WP, et al. Among authors: van gaal lf. N Engl J Med. 2010 Sep 2;363(10):905-17. doi: 10.1056/NEJMoa1003114. N Engl J Med. 2010. PMID: 20818901 Free article. Clinical Trial.
471 results